# Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

Clinical trial · Amgen

- Archive id: nct:NCT07866066
- Published: 2026-10-08
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07866066
- Source URL: https://clinicaltrials.gov/study/NCT07866066
- Provenance: clinicaltrials

## Abstract

The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: MARITIME-T2D-3
- status: NOT_YET_RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 1300
- sponsor: Amgen
- conditions: Diabetes Mellitus, Type 2
- interventions: DRUG: Maridebart cafraglutide; DRUG: Semaglutide
- start date: 2026-11-02
- start date type: ESTIMATED
- primary completion date: 2028-09-04
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.